Enliven Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 3, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 3, 2026

ELVN$51.55+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	As of December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$98,896	$124,117
Marketable securities	363,725	189,323
Restricted cash	—	54
Prepaid expenses and other current assets	12,257	4,633
Total current assets	474,878	318,127
Property and equipment, net	34	458
Operating lease right-of-use assets	383	—
Deferred offering costs	217	—
Other long-term assets	656	7,175
Total assets	$476,168	$325,760
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$2,159	$1,342
Accrued expenses and other current liabilities	14,409	14,573
Total current liabilities	16,568	15,915
Total liabilities	16,568	15,915
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none	—	—
Common stock, par value $0.001; authorized shares - 100,000,000;issued and outstanding shares - 59,440,045 and 48,936,459 atDecember 31, 2025 and 2024, respectively	59	49
Additional paid-in capital	806,373	553,213
Accumulated other comprehensive income	334	55
Accumulated deficit	(347,166)	(243,472)
Total stockholders’ equity	459,600	309,845
Total liabilities and stockholders' equity	$476,168	$325,760

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.